Efficacy of oral naratriptan in the treatment of menstrually related migraine

European Journal of Neurology

Volumn 12, Issue 10, 2005, Pages 774-781

  Massiou, Hélène ^a   Jamin, C ^b   Hinzelin, G ^b   Bidaut Mazel, C ^c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b Laboratoire GlaxoSmithKline ^*  (France)

^c GLAXOSMITHKLINE   (France)

Author keywords

Clinical trial; Menstrually related migraine; Naratriptan

Indexed keywords

ANALGESIC AGENT; ANTIMIGRAINE AGENT; CAFFEINE; CARBASALATE CALCIUM; CYCLIZINE; ELETRIPTAN; ERGOT DERIVATIVE; ERGOTAMINE; LYSINE ACETYLSALICYLATE; METOCLOPRAMIDE; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PLACEBO; RIZATRIPTAN; SEROTONIN 1 AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL MIGRAINE; MENSTRUATION; MIGRAINE; MULTICENTER STUDY; OUTCOMES RESEARCH; PAIN ASSESSMENT; PARESTHESIA; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYMPTOM; THORAX DISEASE; VERTIGO; WORK RESUMPTION;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MENSTRUATION; MIGRAINE DISORDERS; PAIN MEASUREMENT; PATIENT SATISFACTION; PIPERIDINES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 27144541544     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01076.x     Document Type: Article

References (43)

1. Al-Waili NS (2000). Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur J Med Res 19:176-182.
2. Bateman DN (2000). Triptans and migraine. Lancet 335:860-861.
3. Breslau N, Rasmussen K (2001). The impact of migraine: Epidemiology, risk factors and co-morbidities. Neurology 56(6 Suppl. 1):54-512.
4. Burke BE, Olson RD, Cusack BJ (2002). Randomised, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother 56:283-288.
5. Couturier EGM, Bomhof MAM, Neven AK, van Duijn NP (2003). Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 23:302-308.
6. Davies GM, Santanello N, Lipton RB (2000). Determinants of patients satisfaction with migraine therapy. Cephalalgia 20:554-560.
7. De Lignières B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG (1986). Prevention of menstrual migraine by percutaneous estradiol. BMJ 293:1540.
8. Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M (1988). Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 2:113-120.
9. Dowson AJ (2001). Assessing the impact of migraine. Curr Med Res Opin 17:298-309.
10. Epstein MT, Hockaday JM, Hockaday TD (1975). Migraine and reproductive hormones throughout the menstrual cycle. Lancet i: 543-548.
11. Facchinetti F, Bonellie G, Kangasniemi P, Pascual J, Shuaib A (1995a). The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. Obstet Gynecol 86:911-916.
12. Facchinetti F, Bonellie G, Kangasniemi P, Pascual J, Shuaib A, for The Sumatriptan Menstrual Migraine Study Group (1995b). The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. Obstet Gynecol 86:911-916.
13. Headache Classification Committee of the International Headache Society (1988). Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 8(Suppl. 7):1-96.
14. Henry P, Auray JP, Gaudin AF et al. (2002). Prevalence and clinical characteristics of migraine in France. Neurology 59:232-237.
15. Heywood J, BoMhof M, Pradalier A, Thaventhiran L, Winter P, Hassani H, on behalf of The Naratriptan Long-Term Study Group (2000). Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Cephalalgia 20:470-474.
16. IHS (2004). The International Classification of Headache Disorders, 2nd edn. Cephalalgia 24(Suppl. 1):8-160.
17. Klassen A, Elkind A, Asgharnejad MCW, Laurenza A, and The Naratriptan Study Group (1997). Naratriptan is effective and well tolerated in the treatment of acute migraine. Results of a double-blind, placebo controlled parallel-group study. Headache 37:640-645.
18. Lichten EM, Bennett RS, Whitty AJ, Daoud Y (1991). Efficacy of danazol in the control of hormonal migraine. J Reprod Med 36:419-424.
19. Lichten EM, Lichten JB, Whitty A, Pieper D (1996). The confirmation of a biochemical marker for women's hormonal migraine. Headache 36:367-371.
20. Lipton RB, Stewart WF (1998). Migraine headaches: epidemiology and comorbidity. Clin Neurosci 5:2-9.
21. Lipton RB, Stewart WF (1999). Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 39(Suppl. 2):S20-S26.
22. Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T (2004). Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 44:120-130.
23. MacGregor EA, Hackshaw A (2004). Prevalence of migraine on each day of the natural menstrual cycle. Neurology 63:351-353.
24. Massiou H (1999). Is menstrually associated migraine difficult to treat? Neurology 19(Suppl. 24):S13-S18.
25. Massiou H, Pitei D, Poole PH, Sikes C (2000). Efficacy of eletriptan for the treatment of migraine in women, in menstrually associated migraine and in women taking oral contraceptives or hormone replacement therapy: meta-analyses of randomized clinical trials. Cephalalgia 20:435.
26. Matthew N, Asgharnejad MCW, Peykamian M, Laurenza A, Tns G (1997). Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. Neurology 49:1485-1490.
27. Murray SC, Muse KN (1997). Effective treatment of severe menstrual migraine headaches with gonadotrophon-releasing hormone agonist and 'add-back' therapy. Fertil Steril 67:390-393.
28. Nachit-Ouinekh F, Dartigues J-F, Henry P, El Hasnaoui A (2005). Use of the headache impact test (HIT-6) in general practice: relationship with quality of life and severity. Eur J of Neurology, in press.
29. Nett R, Landy S, Shackelford S, Richardson MS, Ames M (2003). Pain free efficacy after treatment with sumatriptan in the mild pain phase of menstrually-associated migraine. Obstet Gynecol 102:835-842.
30. Newman LC, Lipton RB, Lay CL, Solomon S (1998). A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 51:307-309.
31. Newman L, Mannix LK, Landy S et al. (2001). Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomised, double-blind, placebo-controlled study. Headache 41:248-256.
32. O'Dea JP, Davis EH (1990). Tamoxifen in the treatment of menstrual migraine. Neurology 40:1470-1471.
33. Pascual J, Vega P, Diener H-C, Allen C, Vrijens F, Patel K, and The Rizatriptan-Zolmitriptan Study Group (2000). Comparison of rizatriptan 10 mg vs. Zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalagia 20:455-461.
34. Salonen R, Saiers J (1999). Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Cephalagia 19:16-19.
35. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G (1990). Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo-controlled study. Headache 30:705-709.
36. Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR (2000). Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol 96:237-242.
37. Silberstein SD, Massiou H, McCarroll KA, Lines CR (2002). Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 42:917-923.
38. Somerville BW (1972). The influence of progesterone and estradiol upon migraine. Headache 12:93-102.
39. Somerville BW (1975a). Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology 25:239-244.
40. Somerville BW (1975b). Estrogen-withdrawal migraine. II. Attempted prophylaxis continuous estradiol administration. Neurology 25:245-250.
41. Stewart WF, Lipton RB, Celentano DD, Reed ML (1992). Prevalence of migraine in the United States: Relation to age, income, race and other sociodemographic factors. JAMA 287:64-69.
42. Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD (2000). Menstrual cycle and headache in a population sample of migraineurs. Neurology 55:1517-1523.
43. Visser WH, Jasper NMWH, De Vriend RHM, Ferrari MD (1996). Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 16:264-269.